Actively Recruiting
Early Detection of Breast Cancer Spread Using Diffusion Whole Body MRI in Patients with HER2 Positive or High-Risk Triple Negative Breast Cancer
Led by European Institute of Oncology · Updated on 2026-01-06
145
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the usefulness of Diffusion Whole Body Magnetic Resonance Imaging DWB-MRI for early detection of locoregional or distant recurrence in patients with high-risk breast cancer subtypes, specifically HER2-positive or Triple Negative breast cancer. The study aims to see if early diagnosis through this imaging method improves 5-year overall survival compared to current follow-up methods. Breast cancer is a common cancer among women, with distant metastases being the main cause of death, and this trial explores more tailored follow-up based on cancer biology and subtype. Participants will undergo surveillance using DWB-MRI, which involves a detailed MRI protocol including sagittal T1-weighted and T2-weighted sequences of the spine and axial images from head to mid-thigh on a 1.5 Tesla scanner. This imaging technique is being studied to detect metastases early and monitor therapy. The study includes patients who have undergone surgery or neoadjuvant treatment and have no distant metastases at baseline imaging. This approach may help identify patients with low disease burden who might benefit from curative treatments. During the study, participants will be monitored over a period of up to five years. Researchers will assess 5-year overall survival as the primary outcome. Secondary outcomes include survival after local treatment, breast cancer-specific survival, safety of local treatments, assessments of anxiety, health state, coping ability, personality, and patient acceptance of DWB-MRI over 48 months. Participants will be regularly evaluated through imaging and questionnaires, with follow-up care coordinated to study the impact of early detection on prognosis and quality of life.
CONDITIONS
Brief Title
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
Research Team
M
Monica Iorfida, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here